NOTV vs. PMVP, LUNA, ONMD, BIAF, DKDCA, AIKI, ISPC, FOXO, PGEN, and OCGN
Should you be buying Inotiv stock or one of its competitors? The main competitors of Inotiv include PMV Pharmaceuticals (PMVP), Luna Innovations (LUNA), OneMedNet (ONMD), bioAffinity Technologies (BIAF), Data Knights Acquisition (DKDCA), AIkido Pharma (AIKI), iSpecimen (ISPC), FOXO Technologies (FOXO), Precigen (PGEN), and Ocugen (OCGN).
PMV Pharmaceuticals (NASDAQ:PMVP) and Inotiv (NASDAQ:NOTV) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, community ranking, dividends, media sentiment, valuation and earnings.
90.2% of PMV Pharmaceuticals shares are held by institutional investors. Comparatively, 18.2% of Inotiv shares are held by institutional investors. 7.6% of PMV Pharmaceuticals shares are held by insiders. Comparatively, 5.8% of Inotiv shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
PMV Pharmaceuticals has a beta of 1.56, indicating that its share price is 56% more volatile than the S&P 500. Comparatively, Inotiv has a beta of 3.37, indicating that its share price is 237% more volatile than the S&P 500.
In the previous week, PMV Pharmaceuticals had 4 more articles in the media than Inotiv. MarketBeat recorded 5 mentions for PMV Pharmaceuticals and 1 mentions for Inotiv. PMV Pharmaceuticals' average media sentiment score of 0.94 beat Inotiv's score of 0.49 indicating that Inotiv is being referred to more favorably in the news media.
PMV Pharmaceuticals received 3 more outperform votes than Inotiv when rated by MarketBeat users. Likewise, 60.00% of users gave PMV Pharmaceuticals an outperform vote while only 47.37% of users gave Inotiv an outperform vote.
PMV Pharmaceuticals currently has a consensus target price of $5.75, indicating a potential upside of 215.93%. Inotiv has a consensus target price of $6.19, indicating a potential upside of 230.88%. Given PMV Pharmaceuticals' higher probable upside, analysts clearly believe Inotiv is more favorable than PMV Pharmaceuticals.
PMV Pharmaceuticals has a net margin of 0.00% compared to PMV Pharmaceuticals' net margin of -12.90%. PMV Pharmaceuticals' return on equity of -11.23% beat Inotiv's return on equity.
PMV Pharmaceuticals has higher earnings, but lower revenue than Inotiv. PMV Pharmaceuticals is trading at a lower price-to-earnings ratio than Inotiv, indicating that it is currently the more affordable of the two stocks.
Summary
PMV Pharmaceuticals beats Inotiv on 11 of the 18 factors compared between the two stocks.
Get Inotiv News Delivered to You Automatically
Sign up to receive the latest news and ratings for NOTV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NOTV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
